89bio
ETNB
ETNB was delisted on the 29th of October, 2025.
68 hedge funds and large institutions have $408M invested in 89bio in 2020 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 29 increasing their positions, 5 reducing their positions, and 3 closing their positions.
1,000% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 3
480% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 5
90% more capital invested
Capital invested by funds: $215M → $408M (+$193M)
79% more funds holding
Funds holding: 38 → 68 (+30)
3.51% more ownership
Funds ownership: 77.13% → 80.64% (+3.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$50M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$27.5M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$14.6M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$13.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$8.72M |
| 2 |
VA
VR Adviser
New York
|
-$5.8M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.78M |
| 4 |
Morgan Stanley
New York
|
-$1.21M |
| 5 |
JP Morgan Chase
New York
|
-$232K |
ETNB Hedge Fund Activity: Q3 2020 in Review
68 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in 89bio (ETNB) for Q3 2020, worth a combined $408M — up 90% from $215M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ETNB positions and 3 closed out — a net gain of 30 holders — while 29 added to existing stakes and 5 trimmed.
The largest buyer was RA Capital Management, adding an estimated $50M. The largest seller was OrbiMed, cutting an estimated $8.72M.
- 68 institutional investors held 89bio (ETNB) as of Q3 2020, up from 38 in Q2 2020.
- Funds reported $408M of 89bio stock for Q3 2020, up 90% quarter-over-quarter.
- 33 funds opened new 89bio positions in Q3 2020 and 3 closed out, a net change of +30 holders.
- The largest 89bio buyer in Q3 2020 was RA Capital Management, an estimated $50M added.
- The largest 89bio seller in Q3 2020 was OrbiMed, an estimated $8.72M sold.
Based on aggregated 13F filings for Q3 2020.